The Quantitative Decision-making Special Interest Group (QDM SIG) was formed in October 2017. It is a group of statisticians from industry and academia, with experience and interests in statistical methods for quantitative decision-making in drug development. The objectives of the SIG are:
| Corine Baayen (Ferring Pharmaceuticals) |
| Thomas Blondel (Ceva) |
| Daniel Bratton (GSK) |
| Alex Carlton (GSK) (Co-Chair) |
| Paul Frewer (AstraZeneca) |
| Heiko Goette (Merck) |
| Tadhg Guerin (Theravance) (Co-Chair) |
| Kimberley Hacquoil (Exploristics) |
| Serene Jiang (J&J) |
| Kevin Kunzmann (Boehringer Ingelheim) |
| April Li (University of Cambridge) |
| Donia Skanji (Servier) |
| Jesper Madsen (Novo Nordisk) |
| Mads Wessel Pederson (Lundbeck) |
| Caroline Petit (Merck) |
| Emmanuel Pham (Nova Discovery) |
| Franck Poitiers (Sanofi) |
| Gustaf Rydevik (UCB Pharma) |
| Gaëlle Saint-Hilary (Saryga) |
| Nima Shiriati (Roche) |
| Guido Thömmes (Merck) |
| Katie Thorn (GSK) |
| Stefano Vezzoli (Chiesi Farmaceutici) |
| Stig Johan Wiklund (Captario) |
For further information, or to join the QDM SIG, please contact our Co-Chairs:
Alex Carlton (GSK) alex.l.carlton@gsk.com
Tadhg Guerin (Theravance) tguerin@theravance.com
